Dere Willard H 4

What Happened

• Dere Willard H, a director of Metagenomi Therapeutics, was granted a derivative award on 2026-06-09 entitling him to 21,000 shares. The reported acquisition price is $0.00 and the reported immediate value is $0 (transaction code A — award/grant).

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-11 (timely filing).
• Security: derivative award covering 21,000 shares; reported price: $0.00; reported value at grant: $0.
• Shares owned after transaction: not disclosed in the provided filing summary.
• Footnote (F1): Vesting occurs on the earlier of (i) the one‑year anniversary of the grant date or (ii) the Company’s 2027 annual meeting of stockholders, subject to the Reporting Person’s continued service on such vesting date.
• Transaction type: grant/award (A); not a sale or open‑market purchase.

Context

• This was a compensation/award grant, not a sale — it does not represent an immediate market purchase or liquidation by the director. The reported $0.00 acquisition price suggests a restricted stock/unit or similar award with vesting conditions; the filing does not state any immediate cash exchanged. The future economic benefit depends on Metagenomi’s stock price at vesting and the director’s continued service per the vesting terms.